Nexalin Study Shows 77.5 Hz, 15 mA DIFS Cuts Self-Injury and Depression
A pilot study of six female adolescents with non-suicidal self-injury showed 21 days of 77.5 Hz, 15 mA DIFS treatment produced significant reductions in self-injury behaviors, depression and anxiety. TMS-EEG findings revealed decreased Default network connectivity and increased high-gamma interactions in Limbic, Salience/Ventral Attention and Control networks.
1. Pilot Study Design
The study enrolled six female adolescents with non-suicidal self-injury, each receiving 21 daily sessions of 77.5 Hz, 15 mA deep intracranial frequency stimulation using Nexalin’s DIFS platform. Patients were assessed at baseline, post-treatment and during follow-up for self-injury, mood and neurophysiological markers.
2. Clinical Outcomes
Participants demonstrated statistically significant reductions in self-injury behaviors, depression (HAMD-24 scores), anxiety and sleep disturbances, with all six meeting predefined clinical response criteria for depression and five of six for self-injury outcomes. No serious adverse effects were reported; only one mild headache resolved quickly.
3. Neurophysiological Evidence
TMS-EEG recordings showed decreased connectivity in the Default network alongside increased high-gamma interactions in the Limbic, Salience/Ventral Attention and Control networks. These changes provide objective evidence of Nexalin’s technology modulating emotional-control circuitry.
4. Strategic Implications
This publication strengthens Nexalin’s evidence base for non-invasive, high-power neurostimulation in mental health, supporting broader development across insomnia, TBI, PTSD, Alzheimer’s and ADHD indications and positioning the company for larger randomized controlled trials.